በጆርናል ኦቭ ሄማቶሎጂ የታተመው ቁልፍ የ PACE ሙከራ የ 5 ዓመት ክትትል ውጤት መሠረት ፓናቲኒብ (ፖናቲኒብ ፣ አይስሉስግ) ሥር የሰደደ ደረጃ ላይ በሚገኘው ሥር የሰደደ ማዮሎይድ ሉኪሚያ (ሲፒ-ሲኤምኤል) በከባድ የታከሙ ሕመምተኞች ለረጅም ጊዜ ቆይቷል ምላሽ
በአማካኝ በ 56.8 ወራቶች ውስጥ ከ 60 ታካሚዎች መካከል 159% (n = 267) ዋና የሕዋስ ምላሽ (MCyR) አግኝተዋል ፡፡ 54% (n = 144) ታካሚዎች ሙሉ የተንቀሳቃሽ ስልክ ምላሽ ነበራቸው ፡፡ 40% (n = 108) patients achieved a major molecular response (MMR), and 24% (n = 64) achieved a molecular response. During the median follow-up period, at 12 months, 82% of patients achieved MCyR, and at 5 years, an estimated 59% of patients achieved MMR. The most common (≥40%) adverse events (TEAE) were rash (47%), abdominal pain (46%), thrombocytopenia (46%), headache (43%), dry skin (42%) and constipation (41%).
In the entire 270 patient cohort, more than 90% of patients had received at least 2 TKI treatments. Investigators found that the response was related to long-term results. The 5-year progression-free survival (PFS) is expected to be 53%, and the overall survival (OS) is 73%.
የእነዚህ መረጃዎች መለቀቅ አስፈላጊ ክስተት ነው ምክንያቱም ፓናቲኒብ አሁንም ቀደም ሲል የቲኪ አይ ጉድለት ላላቸው ተስማሚ ህመምተኞች (የ T315I ሚውቴሽን በሽተኞችን ጨምሮ) ውጤታማ የህክምና አማራጭ መሆኑን ያሳያል ፡፡
